Abstract: The present invention relates to a Lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to an antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or amelioration of vaginitis containing the same.

Abstract: Provided is a composition for preventing or treating colorectal cancer including a mixed strain of probiotics as an active ingredient, specifically, a composition for preventing, alleviating or treating colorectal cancer including a mixed killed strain of L. casei, L. reuteri or Bi. bifidum. According to the present disclosure, the composition is confirmed to have excellent effects of activating apoptosis-related signaling molecules in colorectal cancer cells and inhibiting the growth of tumors derived from colorectal cancer cells, and thus may be usefully used in various industrial fields such as medicines and foods, for prevention, alleviation, or treatment of colorectal cancer.

Abstract: Disclosed is a Lactobacillus strain having a blood glucose lowering effect and an antioxidant effect, a culture medium of the strain, and a cell-free supernatant of the strain. Further, a composition for lowering a blood glucose level contains the same. A composition having an antioxidant ability contains the same. The Lactobacillus plantarum MG4229 strain according to the present disclosure has excellent blood glucose lowering activity and antioxidant activity, and has excellent acid tolerance, bile tolerance, auto-aggregation, and adhesion to epithelial cells, and thus is suitable for probiotics, and thus may be used in various ways as a composition for preventing or treating diabetes mellitus or a composition having antioxidant ability.

Abstract: Provided are a Lactobacillus helveticus strain and a composition for preventing or treating inflammatory disease containing the same. The Lactobacillus helveticus strain (Accession No. KCTC 14110BP) according to the present invention alleviates symptoms of inflammatory bowel disease, such as weight loss and bowel length reduction, and it does not have side effects that have been seen with existing drug treatment. Therefore, the Lactobacillus helveticus strain can be effectively used for the treatment and prevention of inflammatory disease, particularly inflammatory bowel disease.

Abstract: Provided is a novel Lactobacillus Plantarum strain and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus Plantarum (Accession No. KCTC 14107BP) according to the present invention may inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The Lactobacillus Plantarum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus Plantarum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus Plantarum strain may regulate a concentration of metabolic hormones in blood. Therefore, the Lactobacillus Plantarum strain may be usefully used to prevent or treat a metabolic disease.

Abstract: Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

Abstract: There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.

Abstract: The present invention relates to: human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244; and a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for preventing or treating obesity-related diseases, all of which include the same as an active ingredient. A Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits an anti-obesity activity for inhibiting a lipase enzyme activity, inhibiting preadipocyte differentiation and inhibiting triglyceride accumulation, has an excellent ability to form colonies on the epithelial cells of a digestive tract by means of an excellent auto-aggregation ability, and has resistance to acid and bile, thereby being variously usable as a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for the purpose of treating and preventing obesity-related diseases.

Abstract: The present invention relates to: human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244; and a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for preventing or treating obesity-related diseases, all of which include the same as an active ingredient. A Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits an anti-obesity activity for inhibiting a lipase enzyme activity, inhibiting preadipocyte differentiation and inhibiting triglyceride accumulation, has an excellent ability to form colonies on the epithelial cells of a digestive tract by means of an excellent auto-aggregation ability, and has resistance to acid and bile, thereby being variously usable as a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for the purpose of treating and preventing obesity-related diseases.

Abstract: Disclosed is a Lactobacillus strain having a blood glucose lowering effect and an antioxidant effect, a culture medium of the strain, and a cell-free supernatant of the strain. Further, a composition for lowering a blood glucose level contains the same. A composition having an antioxidant ability contains the same. The Lactobacillus plantarum MG4229 strain according to the present disclosure has excellent blood glucose lowering activity and antioxidant activity, and has excellent acid tolerance, bile tolerance, auto-aggregation, and adhesion to epithelial cells, and thus is suitable for probiotics, and thus may be used in various ways as a composition for preventing or treating diabetes mellitus or a composition having antioxidant ability.

Abstract: The present invention relates to a lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to a antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or ameliorating of vaginitis containing the same.

Abstract: The present invention relates to human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 and to a pharmaceutical composition for the prevention or treatment of obesity-related diseases, containing the same as an active ingredient, and a food composition, quasi-drug composition and functional health food. The Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits anti-obesity activity that inhibits lipase enzyme activity, preadipocyte differentiation and neutral lipid accumulation, has high autoaggregation ability to thus show excellent colony formation ability on the epithelial cells of the digestive tract, and is resistant to acid and bile. Thereby, the Lactobacillus fermentum MG4231 strain or the MG4244 strain can be variously utilized in a pharmaceutical composition for the prevention and treatment of obesity-related diseases, and a food composition, quasi-drug composition and functional health food.